TRML — Tourmaline Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $418.66m
- $160.35m
- 36
- 33
- 56
- 36
Annual cashflow statement for Tourmaline Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.7 | -47.8 | -73.9 | -42.1 | -73.2 |
| Depreciation | |||||
| Non-Cash Items | 1.43 | 4.91 | 10.6 | 14.2 | -0.938 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.61 | 2.31 | 1.1 | -0.168 | -3.15 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -19.2 | -40 | -60.9 | -28.1 | -77.3 |
| Capital Expenditures | -1.29 | -2.44 | -3.04 | -0.056 | -0.009 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -132 | -94 | 58.7 | 3.9 | -194 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -133 | -96.4 | 55.7 | 3.84 | -194 |
| Financing Cash Flow Items | — | -0.277 | 0 | 64.8 | 161 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 131 | 137 | 0.242 | 157 | 161 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -21.4 | 1.02 | -4.94 | 132 | -110 |